{
    "clinical_study": {
        "@rank": "149845", 
        "arm_group": {
            "arm_group_label": "Mitoxantrone Hydrochloride Liposome", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the maximum tolerated dose,the safety and\n      effectiveness of Mitoxantrone Hydrochloride Liposome Injection."
        }, 
        "brief_title": "Phase I Study of Mitoxantrone Hydrochloride Liposome Injection", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Lymphoma", 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "The trial of the dose escalation method is from 18mg/m2 until the maximum tolerated dose and\n      every 3 patient is a dose group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must compliance with the requirements and restrictions listed in the consent\n             form\n\n          -  Patients with Pathology and / or cytologically proven malignant  lymphoma\n\n          -  Patients must be 18-70 years old ,both male and female\n\n          -  Failure of standard chemotherapy\n\n          -  Patients have no better choice and may be benefit from the use of anthracyclines\n\n          -  Patients with  Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2\n\n          -  Objective tumor from the last chemotherapy, biological therapy or other experimental\n             interval treatment least 4 weeks\n\n          -  Expected survival time \u2265 3 months\n\n          -  Patients agreed to take effective contraceptive measures during the trial\n\n          -  Blood routine, liver and kidney function, cardiac function examination in accordance\n             with the following requirements.\n\n        Exclusion Criteria:\n\n          -  Pregnancy and breast-feeding women\n\n          -  Multiple sclerosis\n\n          -  Patients that have histories of ischemic heart disease and heart\n             congestive,arrhythmia that need to be a treatment and significant valvular disease\n\n          -  Patients with heart disease induced by anthracycline\n\n          -  Patients requiring other antineoplastic treatment\n\n          -  Patients with temperature above 38 degrees or active infection that may effects in\n             clinical tests\n\n          -  Patients are allergic to anthracycline and liposomal drugs\n\n          -  Patients are allergic to eggs,egg products,soybean and soybean products\n\n          -  Patients with uncontrolled primary or metastatic brain tumorsMultiple sclerosis\n\n          -  Patients that have histories of ischemic heart disease and heart\n             congestive,arrhythmia that need to be a treatment and significant valvular disease\n\n          -  Patients with heart disease induced by anthracycline\n\n          -  Patients requiring other antineoplastic treatment\n\n          -  Patients with temperature above 38 degrees or active infection that may effects in\n             clinical tests\n\n          -  Patients are allergic to anthracycline and liposomal drugs\n\n          -  Patients are allergic to eggs,egg products,soybean and soybean products\n\n          -  Patients with uncontrolled primary or metastatic brain tumors\n\n          -  Total amount of Doxorubicin(or Pirarubicin)\u2265360mg/m2,Epirubicin \u2265600mg/m2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131688", 
            "org_study_id": "CSPC-HE14\u2160"
        }, 
        "intervention": {
            "arm_group_label": "Mitoxantrone Hydrochloride Liposome", 
            "intervention_name": "Mitoxantrone Hydrochloride Liposome", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mitoxantrone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "safety;malignant lymphoma;", 
        "lastchanged_date": "May 4, 2014", 
        "location": {
            "contact": {
                "last_name": "Yuankai Shi, Ph.D", 
                "phone": "010-87788701"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Hospital ,Chinese Academy of Mddical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Yuankai Shi, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jianliang Yang, Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma", 
        "overall_official": {
            "affiliation": "Cancer Hospital ,Chinese Academy of Mddical Sciences", 
            "last_name": "Yuankai Shi, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose (MTD) of Mitoxantrone Hydrochloride Liposome Injection", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131688"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "source": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}